Peringatan Keamanan

-TDLo oral 17mg/kg (human) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX). PMID: 13535337.
-LD50 intraperitoneal 116mg/kg (mouse) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD. PMID: 13062090.
-LD50 intravenous 72mg/kg (mouse) BEHAVIORAL: ATAXIA. PMID: 14109651.

Captodiame

DB09014

small molecule experimental

Deskripsi

Captodiame, also known as captodiamine, is an antihistamine which is used as a sedative and anxiolytic. It is a derivative of diphenhydramine. Captodiame has been suggested for use in preventing benzodiazepine withdrawal syndrome.

Struktur Molekul 2D

Berat 359.592
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Renal.

Interaksi Obat

678 Data
Buprenorphine Captodiame may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Captodiame.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Captodiame.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Captodiame.
Hydrocodone Captodiame may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Captodiame.
Magnesium sulfate The therapeutic efficacy of Captodiame can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Captodiame may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Captodiame may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Captodiame.
Mirtazapine Captodiame may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Captodiame.
Orphenadrine Captodiame may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Captodiame may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Captodiame.
Pramipexole Captodiame may increase the sedative activities of Pramipexole.
Ropinirole Captodiame may increase the sedative activities of Ropinirole.
Rotigotine Captodiame may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Captodiame.
Sodium oxybate Captodiame may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Captodiame may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Captodiame.
Thalidomide Captodiame may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Captodiame may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Yohimbine The therapeutic efficacy of Captodiame can be increased when used in combination with Yohimbine.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Captodiame.
Dicoumarol The risk or severity of adverse effects can be increased when Captodiame is combined with Dicoumarol.
Phenindione The risk or severity of adverse effects can be increased when Captodiame is combined with Phenindione.
Warfarin The risk or severity of adverse effects can be increased when Captodiame is combined with Warfarin.
Phenprocoumon The risk or severity of adverse effects can be increased when Captodiame is combined with Phenprocoumon.
Acenocoumarol The risk or severity of adverse effects can be increased when Captodiame is combined with Acenocoumarol.
4-hydroxycoumarin The risk or severity of adverse effects can be increased when Captodiame is combined with 4-hydroxycoumarin.
Coumarin The risk or severity of adverse effects can be increased when Captodiame is combined with Coumarin.
(R)-warfarin The risk or severity of adverse effects can be increased when Captodiame is combined with (R)-warfarin.
Ethyl biscoumacetate The risk or severity of adverse effects can be increased when Captodiame is combined with Ethyl biscoumacetate.
Fluindione The risk or severity of adverse effects can be increased when Captodiame is combined with Fluindione.
Clorindione The risk or severity of adverse effects can be increased when Captodiame is combined with Clorindione.
Diphenadione The risk or severity of adverse effects can be increased when Captodiame is combined with Diphenadione.
Tioclomarol The risk or severity of adverse effects can be increased when Captodiame is combined with Tioclomarol.
(S)-Warfarin The risk or severity of adverse effects can be increased when Captodiame is combined with (S)-Warfarin.
Ethanol Captodiame may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Captodiame may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Captodiame.
Fluvoxamine The risk or severity of adverse effects can be increased when Captodiame is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Captodiame is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Captodiame is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Captodiame is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Captodiame is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Captodiame is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Captodiame is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Captodiame is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Captodiame is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Captodiame is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Captodiame is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Captodiame is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Captodiame is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Captodiame is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Captodiame is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Captodiame is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Captodiame is combined with Alaproclate.
Zopiclone The risk or severity of adverse effects can be increased when Captodiame is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Captodiame.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Captodiame.
Tryptophan The risk or severity of CNS depression can be increased when Tryptophan is combined with Captodiame.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Captodiame.
Lorazepam The risk or severity of CNS depression can be increased when Lorazepam is combined with Captodiame.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Captodiame.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Captodiame.
Reserpine The risk or severity of CNS depression can be increased when Reserpine is combined with Captodiame.
Eletriptan The risk or severity of CNS depression can be increased when Eletriptan is combined with Captodiame.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Captodiame.
Temazepam The risk or severity of CNS depression can be increased when Temazepam is combined with Captodiame.
Reboxetine The risk or severity of CNS depression can be increased when Reboxetine is combined with Captodiame.
Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Captodiame.
Butalbital The risk or severity of CNS depression can be increased when Butalbital is combined with Captodiame.
Methysergide The risk or severity of CNS depression can be increased when Methysergide is combined with Captodiame.
Cabergoline The risk or severity of CNS depression can be increased when Cabergoline is combined with Captodiame.
Phenytoin The risk or severity of CNS depression can be increased when Phenytoin is combined with Captodiame.
Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Captodiame.
Clemastine The risk or severity of CNS depression can be increased when Clemastine is combined with Captodiame.
Venlafaxine The risk or severity of CNS depression can be increased when Venlafaxine is combined with Captodiame.
Etomidate The risk or severity of CNS depression can be increased when Etomidate is combined with Captodiame.
Morphine The risk or severity of CNS depression can be increased when Morphine is combined with Captodiame.
Talbutal The risk or severity of CNS depression can be increased when Talbutal is combined with Captodiame.
Pentobarbital The risk or severity of CNS depression can be increased when Pentobarbital is combined with Captodiame.
Valproic acid The risk or severity of CNS depression can be increased when Valproic acid is combined with Captodiame.
Zolmitriptan The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Captodiame.
Codeine The risk or severity of CNS depression can be increased when Codeine is combined with Captodiame.
Dihydroergotamine The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Captodiame.
Amitriptyline The risk or severity of CNS depression can be increased when Amitriptyline is combined with Captodiame.
Tolcapone The risk or severity of CNS depression can be increased when Tolcapone is combined with Captodiame.
Hydromorphone The risk or severity of CNS depression can be increased when Hydromorphone is combined with Captodiame.
Olanzapine The risk or severity of CNS depression can be increased when Olanzapine is combined with Captodiame.
Cetirizine The risk or severity of CNS depression can be increased when Cetirizine is combined with Captodiame.
Protriptyline The risk or severity of CNS depression can be increased when Protriptyline is combined with Captodiame.
Trimethadione The risk or severity of CNS depression can be increased when Trimethadione is combined with Captodiame.
Clobazam The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Captodiame.
Chlorzoxazone The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Captodiame.
Clozapine The risk or severity of CNS depression can be increased when Clozapine is combined with Captodiame.
Meprobamate The risk or severity of CNS depression can be increased when Meprobamate is combined with Captodiame.

Target Protein

5-hydroxytryptamine receptor 2C HTR2C
Sigma non-opioid intracellular receptor 1 SIGMAR1
D(3) dopamine receptor DRD3

Referensi & Sumber

Synthesis reference: Captodiamine synthesis: Hubner Oluf Herman, Petersen Povl Viggo. U.S. Patent 2,830,088 (1958).
Artikel (PubMed)
  • PMID: 15383182
    Mercier-Guyon C, Chabannes JP, Saviuc P: The role of captodiamine in the withdrawal from long-term benzodiazepine treatment. Curr Med Res Opin. 2004 Sep;20(9):1347-55.
  • PMID: 14431646
    PENTNEY BH, BROTHERWOOD RW: Captodiame in anxiety states in general practice. Practitioner. 1960 Aug;185:218-21.
Link

Contoh Produk & Brand

Produk: 0 • International brands: 3
International Brands
  • Covatine — Bailly-Creat
  • Covatix — Lundbeck
  • Suvren — Ayerst

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul